Advanced
Search
  1. Home
  2. Pfizer-BioNTech COVID Vaccine 90.7% Effective in Children 5-11: Shots
Pfizer-BioNTech COVID Vaccine 90.7% Effective in Children 5-11: Shots

Pfizer-BioNTech COVID Vaccine 90.7% Effective in Children 5-11: Shots

  • October 22, 2021
  • 0 Likes
  • 10 Views
  • 0 Comments

Pharmacist LaChandra McGowan prepares a dose of the Pfizer COVID-19 vaccine at a DePaul Community Health-operated clinic in New Orleans in August. Soon, children ages 5-11 could be eligible for Pfizer shots.

Mario Tama / Getty Images


Hide caption

Toggle caption

Mario Tama / Getty Images


Pharmacist LaChandra McGowan prepares a dose of the Pfizer COVID-19 vaccine at a DePaul Community Health-operated clinic in New Orleans in August. Soon, children ages 5-11 could be eligible for Pfizer shots.

Mario Tama / Getty Images

Pfizer and its partner BioNTech say their data supports the approval of their COVID-19 vaccine in children aged 5-11.

The Food and Drug Administration published the briefing document of the companies Friday morning as a prelude to a specialist consultant meeting of the agency planned for Tuesday.

The companies studied a vaccine dose of 10 micrograms in children aged 5 to 11 years, a third of the dose used for adults and older children. The lower dose was chosen to minimize side effects and because it still elicits a strong immune response, the companies said.

In the main clinical study conducted by the companies, the vaccine appeared to be greater than 90% against symptomatic COVID-19. to be effective

No new security issues were identified in the companies’ studies. No cases of heart inflammation were observed in the main study, but only a few thousand children were included in the study, so a rare problem would not necessarily be detected.

The antibody response to the vaccine was similar to that seen in subjects aged 16-25 years.

The FDA is preparing its own analysis, which is expected to be published on Friday.

Thank You For Reading!

Reference: www.npr.org

  • Share:

Leave Your Comment